Immunomedics Company Profile (NASDAQ:IMMU)

About Immunomedics (NASDAQ:IMMU)

Immunomedics logoImmunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:IMMU
  • CUSIP: 45290710
  • Web:
  • Market Cap: $852.72 million
  • Outstanding Shares: 110,298,000
Average Prices:
  • 50 Day Moving Avg: $8.53
  • 200 Day Moving Avg: $6.88
  • 52 Week Range: $2.02 - $9.51
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -13.89
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $3.38 million
  • Price / Sales: 253.88
  • Book Value: ($1.20) per share
  • Price / Book: -6.48
  • EBIDTA: ($63,800,000.00)
  • Net Margins: -3,426.56%
  • Return on Assets: -142.88%
  • Debt-to-Equity Ratio: -0.74%
  • Current Ratio: 0.57%
  • Quick Ratio: 0.56%
  • Average Volume: 2.05 million shs.
  • Beta: 1.71
  • Short Ratio: 13.63
Frequently Asked Questions for Immunomedics (NASDAQ:IMMU)

What is Immunomedics' stock symbol?

Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."

How were Immunomedics' earnings last quarter?

Immunomedics, Inc. (NASDAQ:IMMU) released its quarterly earnings results on Thursday, February, 9th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.13) by $0.03. The company earned $0.38 million during the quarter, compared to analyst estimates of $0.70 million. View Immunomedics' Earnings History.

Where is Immunomedics' stock going? Where will Immunomedics' stock price be in 2017?

3 brokers have issued 1 year target prices for Immunomedics' shares. Their predictions range from $11.00 to $15.00. On average, they expect Immunomedics' share price to reach $13.00 in the next twelve months. View Analyst Ratings for Immunomedics.

Are investors shorting Immunomedics?

Immunomedics saw a increase in short interest in the month of July. As of July 31st, there was short interest totalling 34,023,565 shares, an increase of 1.9% from the July 14th total of 34,673,820 shares. Based on an average trading volume of 1,532,131 shares, the short-interest ratio is currently 22.2 days. Approximately 33.9% of the company's stock are short sold.

Who are some of Immunomedics' key competitors?

Who are Immunomedics' key executives?

Immunomedics' management team includes the folowing people:

  • Jason M. Aryeh, Chairman of the Board
  • Cynthia L. Sullivan, President, Chief Executive Officer, Director
  • Michael R. Garone, Chief Financial Officer, Vice President - Finance
  • David M. Goldenberg, Chief Scientific Officer, Chief Patent Officer, Director
  • Geoffrey F. Cox Ph.D., Independent Director
  • Robert Forrester, Independent Director
  • Brian A. Markison, Lead Independent Director
  • Bob Oliver, Independent Director

Who owns Immunomedics stock?

Immunomedics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (5.02%), State Street Corp (4.37%), Vanguard Group Inc. (4.13%), Farallon Capital Management LLC (3.83%), Palo Alto Investors LLC (2.73%) and First Light Asset Management LLC (1.86%). Company insiders that own Immunomedics stock include Cynthia L Goldenberg, David M Goldenberg, Don C Stark and Mary E Paetzold. View Institutional Ownership Trends for Immunomedics.

Who sold Immunomedics stock? Who is selling Immunomedics stock?

Immunomedics' stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Chicago Equity Partners LLC, Virtu KCG Holdings LLC, First Light Asset Management LLC, Atlantic Trust Group LLC, UBS Asset Management Americas Inc., IFP Advisors Inc and Swiss National Bank. Company insiders that have sold Immunomedics stock in the last year include Don C Stark and Mary E Paetzold. View Insider Buying and Selling for Immunomedics.

Who bought Immunomedics stock? Who is buying Immunomedics stock?

Immunomedics' stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Palo Alto Investors LLC, State Street Corp, Jennison Associates LLC, Goldman Sachs Group Inc., DAFNA Capital Management LLC, EAM Investors LLC and Gotham Asset Management LLC. View Insider Buying and Selling for Immunomedics.

How do I buy Immunomedics stock?

Shares of Immunomedics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Immunomedics' stock price today?

One share of Immunomedics stock can currently be purchased for approximately $7.78.

MarketBeat Community Rating for Immunomedics (NASDAQ IMMU)
Community Ranking:  2.7 out of 5 ( )
Outperform Votes:  123 (Vote Outperform)
Underperform Votes:  101 (Vote Underperform)
Total Votes:  224
MarketBeat's community ratings are surveys of what our community members think about Immunomedics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Immunomedics (NASDAQ:IMMU) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $13.00 (67.10% upside)

Analysts' Ratings History for Immunomedics (NASDAQ:IMMU)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/24/2017Cowen and CompanyReiterated RatingOutperform$15.00LowView Rating Details
7/14/2017Jefferies Group LLCReiterated RatingBuy$11.00LowView Rating Details
5/5/2017Wells Fargo & CompanyUpgradeMarket Perform -> OutperformHighView Rating Details
(Data available from 8/17/2015 forward)


Earnings History for Immunomedics (NASDAQ:IMMU)
Earnings by Quarter for Immunomedics (NASDAQ:IMMU)
Earnings History by Quarter for Immunomedics (NASDAQ IMMU)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/9/2017Q2 2017($0.13)($0.16)$0.70 million$0.38 millionViewListenView Earnings Details
11/2/2016Q117($0.14)($0.17)$0.70 million$0.74 millionViewN/AView Earnings Details
8/17/2016Q416($0.11)($0.17)$0.90 million$0.93 millionViewListenView Earnings Details
5/4/2016Q3($0.13)($0.15)$0.70 million$0.90 millionViewN/AView Earnings Details
2/3/2016Q216($0.14)($0.15)$1.40 million$0.67 millionViewN/AView Earnings Details
11/4/2015Q116($0.14)($0.16)$1.23 million$0.73 millionViewN/AView Earnings Details
8/19/2015Q415($0.13)($0.13)$1.13 million$2.40 millionViewListenView Earnings Details
5/6/2015Q3 2015($0.13)($0.13)$1.07 million$1.18 millionViewN/AView Earnings Details
2/4/2015Q215($0.13)($0.12)$1.73 million$1.00 millionViewN/AView Earnings Details
11/5/2014Q1 2015($0.12)($0.13)$1.18 million$1.07 millionViewN/AView Earnings Details
8/25/2014Q414($0.13)($0.13)$1.20 million$1.20 millionViewN/AView Earnings Details
5/7/2014Q3 2014($0.12)$0.02$1.13 million$1.15 millionViewN/AView Earnings Details
2/10/2014Q214($0.10)($0.10)$1.20 million$1.20 millionViewN/AView Earnings Details
8/22/2013Q4 2013($0.12)($0.09)$0.81 million$1.40 millionViewN/AView Earnings Details
5/8/2013Q3 2013($0.10)$0.11$0.97 million$1.70 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Immunomedics (NASDAQ:IMMU)
2017 EPS Consensus Estimate: ($0.53)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.12)($0.12)($0.12)
Q2 20171($0.15)($0.15)($0.15)
Q3 20171($0.15)($0.15)($0.15)
Q4 20171($0.11)($0.11)($0.11)
(Data provided by Zacks Investment Research)


Dividend History for Immunomedics (NASDAQ:IMMU)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Immunomedics (NASDAQ:IMMU)
Insider Ownership Percentage: 6.60%
Institutional Ownership Percentage: 63.39%
Insider Trades by Quarter for Immunomedics (NASDAQ:IMMU)
Institutional Ownership by Quarter for Immunomedics (NASDAQ:IMMU)
Insider Trades by Quarter for Immunomedics (NASDAQ:IMMU)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/24/2016Don C StarkDirectorSell9,900$2.97$29,403.00View SEC Filing  
8/23/2016Mary E PaetzoldDirectorSell15,000$2.98$44,700.00View SEC Filing  
6/13/2016Cynthia L GoldenbergCEOSell371,990$3.03$1,127,129.70View SEC Filing  
6/8/2016Cynthia L GoldenbergCEOSell41,441$3.62$150,016.42View SEC Filing  
6/8/2016David M GoldenbergChairmanSell353,010$3.88$1,369,678.80View SEC Filing  
6/7/2016Cynthia L GoldenbergCEOSell4,600$4.01$18,446.00View SEC Filing  
6/7/2016David M GoldenbergChairmanSell12,300$3.98$48,954.00View SEC Filing  
6/6/2016Cynthia L GoldenbergCEOSell63,959$4.09$261,592.31View SEC Filing  
6/6/2016David M GoldenbergChairmanSell110,322$4.09$451,216.98View SEC Filing  
6/15/2015David M GoldenbergChairmanSell210,991$4.08$860,843.28View SEC Filing  
6/12/2015Brian A MarkisonDirectorSell5,564$4.22$23,480.08View SEC Filing  
6/12/2015David M GoldenbergChairmanSell359,653$4.32$1,553,700.96View SEC Filing  
6/9/2015Mary E PaetzoldDirectorSell4,677$4.60$21,514.20View SEC Filing  
6/5/2015Don C StarkDirectorSell5,732$4.14$23,730.48View SEC Filing  
12/11/2014Mary E PaetzoldDirectorSell10,000$4.71$47,100.00View SEC Filing  
12/9/2014Don C StarkDirectorSell5,500$4.51$24,805.00View SEC Filing  
9/13/2013Don StarkDirectorSell10,000$6.08$60,800.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Immunomedics (NASDAQ:IMMU)
Latest Headlines for Immunomedics (NASDAQ:IMMU)
DateHeadline logoImmunomedics' (IMMU) Q4 2017 Results - Earnings Call Transcript - Seeking Alpha - August 17 at 12:52 AM logoImmunomedics, Inc. – Value Analysis (NASDAQ:IMMU) : August 17, 2017 - August 17 at 12:52 AM logoAfter-Hours Earnings Report for August 16, 2017 : CSCO, NTAP, LB, VIPS, CACI, BGG, SPTN, IMMU, GPRK, PBIO - Nasdaq - August 16 at 7:49 PM logoImmunomedics Announces Fiscal 2017 Results and Strategic Developments; Reiterates Guidance on BLA Submission ... - GlobeNewswire (press release) - August 16 at 7:49 PM logoImmunomedics Announces Fiscal 2017 Results and Strategic Developments; Reiterates Guidance on BLA Submission Timeline - August 16 at 7:49 PM logoImmunomedics reports 4Q loss - August 16 at 7:49 PM logoZacks Investment Research Lowers Immunomedics, Inc. (IMMU) to Hold - August 11 at 12:28 AM logoImmunomedics Announces Conference Call and Webcast for Fourth Quarter and Fiscal Year 2017 Results - August 7 at 7:15 PM logoImmunomedics, Inc. (IMMU) Stock Rating Lowered by BidaskClub - August 4 at 11:52 PM logoBRIEF-Immunomedics, Covance enter into master services agreement - August 4 at 8:07 PM logoImmunomedics, Inc. breached its 50 day moving average in a Bearish Manner : IMMU-US : August 3, 2017 - August 3 at 7:57 PM logoImmunomedics, Inc. (IMMU) Receives Consensus Recommendation of "Buy" from Brokerages - July 25 at 3:07 PM logoCowen and Company Reaffirms Outperform Rating for Immunomedics, Inc. (NASDAQ:IMMU) - July 24 at 4:10 PM logoImmunomedics, Inc. (IMMU) Raised to "Buy" at Zacks Investment Research - July 18 at 12:56 AM logoFY2019 Earnings Forecast for Immunomedics, Inc. (NASDAQ:IMMU) Issued By Jefferies Group - July 17 at 11:11 AM logoJefferies Group LLC Reaffirms "Buy" Rating for Immunomedics, Inc. (IMMU) - July 15 at 4:12 PM logoJefferies Group Comments on Immunomedics, Inc.'s FY2022 Earnings (IMMU) - July 14 at 3:56 PM logoPublished Results from Clinical Trials Demonstrate Therapeutic Potential for Immunomedics’ Sacituzumab Govitecan (IMMU-132) in the Treatment of Metastatic Solid Cancers - July 10 at 7:51 PM logoETFs with exposure to Immunomedics, Inc. : July 10, 2017 - July 10 at 7:51 PM logoPre-Market Most Active for Jul 3, 2017 : SIRI, MU, PBR, IMMU, VIPS, BAC, USLV, TSLA, SPIL, RAD, NRG, CHK - Nasdaq - July 3 at 7:20 PM logoForm 8-K IMMUNOMEDICS INC For: Jun 29 - - July 1 at 1:00 AM logoImmunomedics Announces Results of Special Stockholder Meeting - Nasdaq - June 30 at 5:14 AM logoOptions Traders Expect Huge Moves in Immunomedics (IMMU) Stock - June 30 at 12:10 AM logoImmunomedics Announces Results of Special Stockholder Meeting - June 30 at 12:10 AM logoImmunomedics, Inc. (IMMU) Short Interest Update - June 28 at 7:14 AM logoETFs with exposure to Immunomedics, Inc. : June 27, 2017 - June 27 at 6:06 PM logoETFs with exposure to Immunomedics, Inc. : June 16, 2017 - June 16 at 6:44 PM logoImmunomedics, Inc. (IMMU) Given a $9.00 Price Target by Jefferies Group LLC Analysts - June 11 at 10:52 PM logoThree Junior Biotechs Ready to Run (IMMU, STDY) - June 7 at 5:28 PM logoETFs with exposure to Immunomedics, Inc. : June 5, 2017 - June 5 at 5:56 PM logoImmunomedics, Inc. (IMMU) Raised to "Hold" at ValuEngine - June 4 at 11:14 AM logoImmunomedics to Present at Jefferies 2017 Global Healthcare Conference - June 1 at 6:44 PM logoImmunomedics, Inc. (IMMU) Coverage Initiated at Cowen and Company - May 26 at 2:52 PM logoETFs with exposure to Immunomedics, Inc. : May 25, 2017 - May 26 at 2:17 AM logoImmunomedics, Inc. :IMMU-US: Earnings Analysis: Q3, 2017 By the Numbers : May 24, 2017 - May 24 at 11:33 AM logoCompany Spotlight: Immunomedics - May 12 at 6:36 PM logoEdited Transcript of IMMU earnings conference call or presentation 10-May-17 9:00pm GMT - May 12 at 2:04 AM logoImmunomedics, Inc. (IMMU) Short Interest Up 12.4% in April - May 11 at 7:34 AM logoBRIEF-Immunomedics Q3 loss per share $0.55 - May 10 at 6:22 PM logoImmunomedics Announces Third Quarter Fiscal 2017 Results and Clinical Program Developments - May 10 at 6:22 PM logoImmunomedics reports 3Q loss - May 10 at 6:22 PM logoImmunomedics Announces Conference Call and Webcast for Third Quarter Fiscal 2017 Results - May 10 at 1:20 PM logoEquities Analysts Issue Forecasts for Immunomedics, Inc.'s FY2017 Earnings (IMMU) - May 10 at 9:58 AM logoImmunomedics (IMMU) Earns Daily Coverage Optimism Score of 0.19 - May 9 at 12:50 AM logoImmunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : May 8, 2017 - May 8 at 5:33 PM logoBiotech Stocks Under Scanner -- Rexahn Pharma, Peregrine Pharma, Immunomedics, and Protalix BioTherapeutics - May 8 at 7:18 AM logoImmunomedics Breaks Out, But Will It Last? - May 8 at 7:18 AM logoDid Immunomedics Rise Too Much as Seattle Genetics Deal Terminated? - May 6 at 9:50 AM logoImmunomedics (IMMU) Receives Daily Media Sentiment Score of 0.22 - May 5 at 11:22 PM logoBRIEF-Immunomedics announces private placement offering - May 5 at 10:54 PM



Immunomedics (IMMU) Chart for Thursday, August, 17, 2017

This page was last updated on 8/17/2017 by Staff